News & media

November 17, 2020
Casma Therapeutics Appoints Nagesh Mahanthappa, Ph.D., MBA, to Board of Directors

CAMBRIDGE, Mass.-November 17, 2020 – Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced the appointment of Nagesh Mahanthappa, Ph.D., MBA, to its Board of Directors. “We are pleased to welcome Nagesh to our Board of Directors at this significant next stage of Casma’s development,” stated […]

September 10, 2020
Casma Therapeutics Announces $50 Million Series B Financing

Funding led by The Column Group Proceeds will be used to advance Casma’s First-in-Class TRPML1 agonist in muscular dystrophy and enable preclinical proof-of-concept for the Company’s novel autophagy degrader platform CAMBRIDGE, Mass.-September 10, 2020 –Casma Therapeutics, Inc., a biotechnology company harnessing autophagy and the lysosome to design powerful new medicines, today announced the completion of a […]

January 13, 2020
Casma Therapeutics Appoints Two Experts in Lysosomal Proteostasis Pathways and Functional Genomics to Scientific Advisory Board

CAMBRIDGE, Mass.- January 13, 2020 – Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced that Christian Grimm, Ph.D., and Martin Kampmann, Ph.D., will join its scientific advisory board. “Christian and Martin are at the vanguard of their respective fields, known for applying cutting edge technologies to […]

October 16, 2019
Casma Therapeutics Appoints Renowned Proteomic Specialist Steven Gygi to Scientific Advisory Board

CAMBRIDGE, Mass. – October 16, 2019 – Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced that Steven Gygi, Ph.D., will join its scientific advisory board. A professor of cell biology at Harvard Medical School, Gygi brings considerable expertise in applying mass spectrometry-based technologies to the field of […]

September 23, 2019
Casma Therapeutics Named a 2019 “Fierce 15” Biotech Company

CAMBRIDGE, Mass., September 23, 2019 — Casma Therapeutics today announced that it has been named to the 2019 Fierce 15 list by FierceBiotech for its pioneering work to harness the potential of autophagy to design powerful new medicines. The award honors the most promising private biotechnology companies in the world. Casma has built a robust product engine to identify […]

May 29, 2019
Casma Therapeutics Receives Grant from Michael J. Fox Foundation to Support Parkinson’s Drug Development

CAMBRIDGE, Mass., May 29, 2019 —  Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced receipt of a Therapeutic Pipeline Program research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support development of a novel class of drugs to treat Parkinson’s disease. […]

April 12, 2019
Casma Therapeutics Named one of the Boston Business Journal’s Best Places to Work

CAMBRIDGE, Mass. – April 12, 2019 – Casma Therapeutics, a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced that the company has been named a winner of the Best Places to Work award sponsored by the Boston Business Journal. The Boston Business Journal’s Best Places to Work awards are designed to honor […]

March 26, 2019
Casma Therapeutics Establishes Scientific Advisory Board with Appointments of Leading Autophagy and Neuroscience Researchers

CAMBRIDGE, Mass. – March 26, 2019 – Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced the appointments of Sascha Martens, Ph.D., and Pietro De Camilli, M.D., as the first members of Casma’s scientific advisory board. Martens, an expert in autophagy research, is currently professor and head […]

December 12, 2018
Casma Therapeutics Strengthens Leadership Team with Appointment of Chief Operating Officer, Vice President of People & Culture

CAMBRIDGE, Mass. – Dec. 12, 2018 – Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced the appointment of two senior executives who will help lead Casma through its next phase of growth. Caren Block, Casma’s new vice president of people & culture, has extensive experience in […]

December 6, 2018
Casma Therapeutics Licenses Technology to Advance Autophagy-Based Drug Discovery

CAMBRIDGE, Mass., Dec. 6, 2018 – Casma Therapeutics, Inc. today announced an exclusive and nonexclusive license to technology developed at The University of Texas Southwestern Medical Center that will advance the company’s drive to harness the natural cellular processes of autophagy to design powerful new medicines for a broad range of diseases.The license includes commercial rights to a […]

Page 2 of 3